Nabiximols vs. Cannabis Decoction for MS Spasticity: What a New Formulation Comparison Study Found
The nabiximols discontinuation MS spasticity study highlights that most patients eventually stop nabiximols, with some switching to cannabis decoction experiencing further symptom improvement and fewer side effects. This retrospective cohort provides…
Nabiximols for MS: What a New Meta-Analysis Shows Beyond Spasticity
nabiximols multiple sclerosis: A June 25, 2026 meta-analysis pooling 2,949 multiple sclerosis patients found nabiximols linked to significant improvement in bladder function, sleep disruption, spasm quality, and gait beyond its approved spasticity use.…
Cannabis-Based Spray Shown Feasible and Safe for Alzheimer’s Agitation in UK Care Homes
The nabiximols Alzheimer agitation trial demonstrated that administering this cannabis-based spray is feasible and safe for patients in UK care homes. Despite challenges, the study showed perfect adherence and no adverse drug reactions. These results…
Cannabis-Based Spray Shows Early Safety Promise for Alzheimer’s Agitation—But Proof of Efficacy Still Awaited
The nabiximols oromucosal spray feasibility trial demonstrated safe administration in Alzheimer's patients with agitation. Despite challenges, the study showed full adherence and no adverse reactions. These findings support larger trials to evaluate…